Download PDF
Semin Respir Crit Care Med 2017; 38(06): 726-736
DOI: 10.1055/s-0037-1607993
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Reversal of Oral Anticoagulants for Intracerebral Hemorrhage Patients: Best Strategies

Lanting Fuh
1   Department of Pharmacy, Massachusetts General Hospital, Boston, Massachusetts
,
Jonathan H. Sin
1   Department of Pharmacy, Massachusetts General Hospital, Boston, Massachusetts
,
Joshua N. Goldstein
2   Department of Emergency Medicine, Harvard Medical School, Boston, Massachusetts
,
Bryan D. Hayes
1   Department of Pharmacy, Massachusetts General Hospital, Boston, Massachusetts
2   Department of Emergency Medicine, Harvard Medical School, Boston, Massachusetts
› Author Affiliations
Further Information

Publication History

Publication Date:
20 December 2017 (online)

   Permissions and Reprints

Abstract

In patients with acute intracerebral hemorrhage (ICH), one of the major concerns is ongoing bleeding or ICH expansion. Anticoagulated patients are at higher risk of ongoing expansion and worse outcome. It may be that rapid anticoagulation reversal can reduce the risk of expansion and improve clinical outcome. For those taking coumarins, the best available evidence suggests that intravenous vitamin K combined with four-factor prothrombin complex concentrate (4F-PCC) is the most rapid and effective regimen to restore hemostasis. For those on dabigatran, the highest quality data available for reversal are for idarucizumab, although it is not yet clear whether patients derive clinical benefit from this reversal. In the absence or failure of idarucizumab, activated prothrombin complex concentrate (aPCC) is recommended. For those on factor Xa inhibitors, the ideal reversal agent is not clear. Many providers use 4F-PCC or aPCC, but more specific agents are in clinical trials and may soon be available. In addition, the half-lives of the non–vitamin K antagonists are relatively short compared with warfarin, and so some patients may not have a clinically relevant coagulopathy at the time of presentation. Overall, the optimal reversal agent, when one is required, is a function of which anticoagulant the patient is taking.

Keywords

cerebral hemorrhage - anticoagulants - warfarin - dabigatran - rivaroxaban
 

  • References

  • 1 Morotti A, Goldstein JN. Diagnosis and management of acute intracerebral hemorrhage. Emerg Med Clin North Am 2016; 34 (04) 883-899
    CrossrefPubMedGoogle Scholar
  • 2 Morotti A, Goldstein JN. New oral anticoagulants and their reversal agents. Curr Treat Options Neurol 2016; 18 (11) 47
    CrossrefPubMedGoogle Scholar
  • 3 Steiner T, Poli S, Griebe M. , et al. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial. Lancet Neurol 2016; 15 (06) 566-573
    CrossrefPubMedGoogle Scholar
  • 4 Holbrook A, Schulman S, Witt DM. , et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e152S-e184S
    CrossrefPubMedGoogle Scholar
  • 5 García-Rodríguez LA, Gaist D, Morton J, Cookson C, González-Pérez A. Antithrombotic drugs and risk of hemorrhagic stroke in the general population. Neurology 2013; 81 (06) 566-574
    CrossrefPubMedGoogle Scholar
  • 6 Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Stroke 2005; 36 (07) 1588-1593
    CrossrefPubMedGoogle Scholar
  • 7 Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med 2004; 164 (08) 880-884
    CrossrefPubMedGoogle Scholar
  • 8 Ikram MA, Wieberdink RG, Koudstaal PJ. International epidemiology of intracerebral hemorrhage. Curr Atheroscler Rep 2012; 14 (04) 300-306
    CrossrefPubMedGoogle Scholar
  • 9 Huhtakangas J, Tetri S, Juvela S, Saloheimo P, Bode MK, Hillbom M. Effect of increased warfarin use on warfarin-related cerebral hemorrhage: a longitudinal population-based study. Stroke 2011; 42 (09) 2431-2435
    CrossrefPubMedGoogle Scholar
  • 10 Flaherty ML, Kissela B, Woo D. , et al. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology 2007; 68 (02) 116-121
    CrossrefPubMedGoogle Scholar
  • 11 Cucchiara B, Messe S, Sansing L, Kasner S, Lyden P. ; CHANT Investigators. Hematoma growth in oral anticoagulant related intracerebral hemorrhage. Stroke 2008; 39 (11) 2993-2996
    CrossrefPubMedGoogle Scholar
  • 12 Flibotte JJ, Hagan N, O'Donnell J, Greenberg SM, Rosand J. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology 2004; 63 (06) 1059-1064
    CrossrefPubMedGoogle Scholar
  • 13 Dentali F, Ageno W, Crowther M. Treatment of coumarin-associated coagulopathy: a systematic review and proposed treatment algorithms. J Thromb Haemost 2006; 4 (09) 1853-1863
    CrossrefPubMedGoogle Scholar
  • 14 Kalus JS. Pharmacologic interventions for reversing the effects of oral anticoagulants. Am J Health Syst Pharm 2013; 70 (10) (Suppl. 01) S12-S21
    CrossrefPubMedGoogle Scholar
  • 15 Brott T, Broderick J, Kothari R. , et al. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke 1997; 28 (01) 1-5
    CrossrefPubMedGoogle Scholar
  • 16 Kazui S, Naritomi H, Yamamoto H, Sawada T, Yamaguchi T. Enlargement of spontaneous intracerebral hemorrhage. Incidence and time course. Stroke 1996; 27 (10) 1783-1787
    CrossrefPubMedGoogle Scholar
  • 17 Huttner HB, Schellinger PD, Hartmann M. , et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke 2006; 37 (06) 1465-1470
    CrossrefPubMedGoogle Scholar
  • 18 Hemphill III JC, Greenberg SM, Anderson CS. , et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2015; 46 (07) 2032-2060
    CrossrefPubMedGoogle Scholar
  • 19 Britt RB, Brown JN. Characterizing the severe reactions of parenteral vitamin K1. Clin Appl Thromb Hemost 2016; 1076029616674825
    PubMedGoogle Scholar
  • 20 Lubetsky A, Yonath H, Olchovsky D, Loebstein R, Halkin H, Ezra D. Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch Intern Med 2003; 163 (20) 2469-2473
    CrossrefPubMedGoogle Scholar
  • 21 Crowther MA, Douketis JD, Schnurr T. , et al. Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial. Ann Intern Med 2002; 137 (04) 251-254
    CrossrefPubMedGoogle Scholar
  • 22 Watson HG, Baglin T, Laidlaw SL, Makris M, Preston FE. A comparison of the efficacy and rate of response to oral and intravenous vitamin K in reversal of over-anticoagulation with warfarin. Br J Haematol 2001; 115 (01) 145-149
    CrossrefPubMedGoogle Scholar
  • 23 Frontera JA, Lewin III JJ, Rabinstein AA. , et al. Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. Neurocrit Care 2016; 24 (01) 6-46
    CrossrefPubMedGoogle Scholar
  • 24 Brophy GM, Human T, Shutter L. Emergency neurological life support: pharmacotherapy. Neurocrit Care 2015; 23 (Suppl. 02) S48-S68
    CrossrefPubMedGoogle Scholar
  • 25 Pandey S, Vyas GN. Adverse effects of plasma transfusion. Transfusion 2012; 52 (Suppl. 01) 65S-79S
    CrossrefPubMedGoogle Scholar
  • 26 Marshall AL, Levine M, Howell ML. , et al. Dose-associated pulmonary complication rates after fresh frozen plasma administration for warfarin reversal. J Thromb Haemost 2016; 14 (02) 324-330
    CrossrefPubMedGoogle Scholar
  • 27 Yazer MH. The how's and why's of evidence based plasma therapy. Korean J Hematol 2010; 45 (03) 152-157
    CrossrefPubMedGoogle Scholar
  • 28 Abdel-Wahab OI, Healy B, Dzik WH. Effect of fresh-frozen plasma transfusion on prothrombin time and bleeding in patients with mild coagulation abnormalities. Transfusion 2006; 46 (08) 1279-1285
    CrossrefPubMedGoogle Scholar
  • 29 Holland LL, Brooks JP. Toward rational fresh frozen plasma transfusion: the effect of plasma transfusion on coagulation test results. Am J Clin Pathol 2006; 126 (01) 133-139
    CrossrefPubMedGoogle Scholar
  • 30 Lee SB, Manno EM, Layton KF, Wijdicks EF. Progression of warfarin-associated intracerebral hemorrhage after INR normalization with FFP. Neurology 2006; 67 (07) 1272-1274
    CrossrefPubMedGoogle Scholar
  • 31 Goldstein JN, Thomas SH, Frontiero V. , et al. Timing of fresh frozen plasma administration and rapid correction of coagulopathy in warfarin-related intracerebral hemorrhage. Stroke 2006; 37 (01) 151-155
    CrossrefPubMedGoogle Scholar
  • 32 Cada DJ, Levien TL, Baker DE. Prothrombin complex concentrate. Hosp Pharm 2013; 48 (11) 951-957
    CrossrefPubMedGoogle Scholar
  • 33 Goldstein JN, Refaai MA, Milling Jr TJ. , et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. Lancet 2015; 385 (9982): 2077-2087
    CrossrefPubMedGoogle Scholar
  • 34 Sarode R, Milling Jr TJ, Refaai MA. , et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation 2013; 128 (11) 1234-1243
    CrossrefPubMedGoogle Scholar
  • 35 Parry-Jones AR, Di Napoli M, Goldstein JN. , et al. Reversal strategies for vitamin K antagonists in acute intracerebral hemorrhage. Ann Neurol 2015; 78 (01) 54-62
    CrossrefPubMedGoogle Scholar
  • 36 Kuramatsu JB, Gerner ST, Schellinger PD. , et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA 2015; 313 (08) 824-836
    CrossrefPubMedGoogle Scholar
  • 37 Sin JH, Berger K, Lesch CA. Four-factor prothrombin complex concentrate for life-threatening bleeds or emergent surgery: a retrospective evaluation. J Crit Care 2016; 36: 166-172
    CrossrefPubMedGoogle Scholar
  • 38 Gorlin J, Kinney S, Fung MK, Tinmouth A. ; BEST Collaborative. Prothrombin complex concentrate for emergent reversal of warfarin: an international survey of hospital protocols. Vox Sang 2017; 112 (06) 595-597
    CrossrefPubMedGoogle Scholar
  • 39 Klein L, Peters J, Miner J, Gorlin J. Evaluation of fixed dose 4-factor prothrombin complex concentrate for emergent warfarin reversal. Am J Emerg Med 2015; 33 (09) 1213-1218
    CrossrefPubMedGoogle Scholar
  • 40 Hirri HM, Green PJ. Audit of warfarin reversal using a new Octaplex reduced dose protocol. Transfus Apheresis Sci 2014; 51 (02) 141-145
    CrossrefPubMedGoogle Scholar
  • 41 Khorsand N, Veeger NJ, van Hest RM, Ypma PF, Heidt J, Meijer K. An observational, prospective, two-cohort comparison of a fixed versus variable dosing strategy of prothrombin complex concentrate to counteract vitamin K antagonists in 240 bleeding emergencies. Haematologica 2012; 97 (10) 1501-1506
    CrossrefPubMedGoogle Scholar
  • 42 Khorsand N, Veeger NJ, Muller M. , et al. Fixed versus variable dose of prothrombin complex concentrate for counteracting vitamin K antagonist therapy. Transfus Med 2011; 21 (02) 116-123
    CrossrefPubMedGoogle Scholar
  • 43 Varga C, Al-Touri S, Papadoukakis S, Caplan S, Kahn S, Blostein M. The effectiveness and safety of fixed low-dose prothrombin complex concentrates in patients requiring urgent reversal of warfarin. Transfusion 2013; 53 (07) 1451-1458 , quiz 1450
    CrossrefPubMedGoogle Scholar
  • 44 Abdoellakhan RA, Miah IP, Khorsand N, Meijer K, Jellema K. Fixed versus variable dosing of prothrombin complex concentrate in vitamin K antagonist-related intracranial hemorrhage: a retrospective analysis. Neurocrit Care 2017; 26 (01) 64-69
    CrossrefPubMedGoogle Scholar
  • 45 Appleby N, Groarke E, Crowley M. , et al. Reversal of warfarin anticoagulation using prothrombin complex concentrate at 25 IU kg(-1) : results of the RAPID study. Transfus Med 2017; 27 (01) 66-71
    CrossrefPubMedGoogle Scholar
  • 46 Frontera JA, Gordon E, Zach V. , et al. Reversal of coagulopathy using prothrombin complex concentrates is associated with improved outcome compared to fresh frozen plasma in warfarin-associated intracranial hemorrhage. Neurocrit Care 2014; 21 (03) 397-406
    CrossrefPubMedGoogle Scholar
  • 47 Hanger HC, Geddes JA, Wilkinson TJ, Lee M, Baker AE. Warfarin-related intracerebral haemorrhage: better outcomes when reversal includes prothrombin complex concentrates. Intern Med J 2013; 43 (03) 308-316
    CrossrefPubMedGoogle Scholar
  • 48 Kuwashiro T, Yasaka M, Itabashi R. , et al. Effect of prothrombin complex concentrate on hematoma enlargement and clinical outcome in patients with anticoagulant-associated intracerebral hemorrhage. Cerebrovasc Dis 2011; 31 (02) 170-176
    CrossrefPubMedGoogle Scholar
  • 49 Jones GM, Erdman MJ, Smetana KS, Mohrien KM, Vandigo JE, Elijovich L. 3-factor versus 4-factor prothrombin complex concentrate for warfarin reversal in severe bleeding: a multicenter, retrospective, propensity-matched pilot study. J Thromb Thrombolysis 2016; 42 (01) 19-26
    CrossrefPubMedGoogle Scholar
  • 50 Al-Majzoub O, Rybak E, Reardon DP, Krause P, Connors JM. Evaluation of warfarin reversal with 4-factor prothrombin complex concentrate compared to 3-factor prothrombin complex concentrate at a Tertiary Academic Medical Center. J Emerg Med 2016; 50 (01) 7-13
    CrossrefPubMedGoogle Scholar
  • 51 Voils SA, Holder MC, Premraj S, Catlin JR, Allen BR. Comparative effectiveness of 3- versus 4-factor prothrombin complex concentrate for emergent warfarin reversal. Thromb Res 2015; 136 (03) 595-598
    CrossrefPubMedGoogle Scholar
  • 52 Fischer D, Sorensen J, Fontaine GV. Three-factor versus four-factor prothrombin complex concentrate for the emergent management of warfarin-associated intracranial hemorrhage. Neurocrit Care 2017; DOI: 10.1007/s12028-017-0374-y.
    CrossrefPubMedGoogle Scholar
  • 53 Wójcik C, Schymik ML, Cure EG. Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy. Int J Emerg Med 2009; 2 (04) 217-225
    CrossrefPubMedGoogle Scholar
  • 54 Yin EB, Tan B, Nguyen T. , et al. Safety and effectiveness of factor VIII inhibitor bypassing activity (FEIBA) and fresh frozen plasma in oral anticoagulant-associated intracranial hemorrhage: a retrospective analysis. Neurocrit Care 2017; 27 (01) 51-59
    CrossrefPubMedGoogle Scholar
  • 55 Aledort LM. Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues. Haemophilia 2008; 14 (01) 39-43
    CrossrefPubMedGoogle Scholar
  • 56 Mayer SA, Brun NC, Begtrup K. , et al; Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005; 352 (08) 777-785
    CrossrefPubMedGoogle Scholar
  • 57 Mayer SA, Brun NC, Begtrup K. , et al; FAST Trial Investigators. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2008; 358 (20) 2127-2137
    CrossrefPubMedGoogle Scholar
  • 58 Chapman SA, Irwin ED, Abou-Karam NM. , et al. Comparison of 3-factor prothrombin complex concentrate and low-dose recombinant factor VIIa for warfarin reversal. World J Emerg Surg 2014; 9: 27
    CrossrefPubMedGoogle Scholar
  • 59 Woo CH, Patel N, Conell C. , et al. Rapid warfarin reversal in the setting of intracranial hemorrhage: a comparison of plasma, recombinant activated factor VII, and prothrombin complex concentrate. World Neurosurg 2014; 81 (01) 110-115
    CrossrefPubMedGoogle Scholar
  • 60 Pinner NA, Hurdle AC, Oliphant C, Reaves A, Lobo B, Sills A. Treatment of warfarin-related intracranial hemorrhage: a comparison of prothrombin complex concentrate and recombinant activated factor VII. World Neurosurg 2010; 74 (06) 631-635
    CrossrefPubMedGoogle Scholar
  • 61 Ilyas C, Beyer GM, Dutton RP, Scalea TM, Hess JR. Recombinant factor VIIa for warfarin-associated intracranial bleeding. J Clin Anesth 2008; 20 (04) 276-279
    CrossrefPubMedGoogle Scholar
  • 62 Brody DL, Aiyagari V, Shackleford AM, Diringer MN. Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage. Neurocrit Care 2005; 2 (03) 263-267
    CrossrefPubMedGoogle Scholar
  • 63 O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006; 295 (03) 293-298
    CrossrefPubMedGoogle Scholar
  • 64 Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2004; 2 (10) 1700-1708
    CrossrefPubMedGoogle Scholar
  • 65 Diringer MN, Skolnick BE, Mayer SA. , et al. Thromboembolic events with recombinant activated factor VII in spontaneous intracerebral hemorrhage: results from the Factor Seven for Acute Hemorrhagic Stroke (FAST) trial. Stroke 2010; 41 (01) 48-53
    CrossrefPubMedGoogle Scholar
  • 66 DeLoughery E, Avery B, DeLoughery TG. Retrospective study of rFVIIa, 4-factor PCC, and a rFVIIa and 3-factor PCC combination in improving bleeding outcomes in the warfarin and non-warfarin patient. Am J Hematol 2016; 91 (07) 705-708
    CrossrefPubMedGoogle Scholar
  • 67 Nishijima DK, Dager WE, Schrot RJ, Holmes JF. The efficacy of factor VIIa in emergency department patients with warfarin use and traumatic intracranial hemorrhage. Acad Emerg Med 2010; 17 (03) 244-251
    CrossrefPubMedGoogle Scholar
  • 68 Skolnick BE, Mathews DR, Khutoryansky NM, Pusateri AE, Carr ME. Exploratory study on the reversal of warfarin with rFVIIa in healthy subjects. Blood 2010; 116 (05) 693-701
    CrossrefPubMedGoogle Scholar
  • 69 Dowlatshahi D, Demchuk AM, Flaherty ML, Ali M, Lyden PL, Smith EE. ; VISTA Collaboration. Defining hematoma expansion in intracerebral hemorrhage: relationship with patient outcomes. Neurology 2011; 76 (14) 1238-1244
    CrossrefPubMedGoogle Scholar
  • 70 Davis SM, Broderick J, Hennerici M. , et al; Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology 2006; 66 (08) 1175-1181
    CrossrefPubMedGoogle Scholar
  • 71 Sørensen B, Spahn DR, Innerhofer P, Spannagl M, Rossaint R. Clinical review: prothrombin complex concentrates--evaluation of safety and thrombogenicity. Crit Care 2011; 15 (01) 201
    CrossrefPubMedGoogle Scholar
  • 72 Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med 2013; 368 (14) 1272-1274
    CrossrefPubMedGoogle Scholar
  • 73 Graham DJ, Reichman ME, Wernecke M. , et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 2015; 131 (02) 157-164
    CrossrefPubMedGoogle Scholar
  • 74 Schiele F, van Ryn J, Canada K. , et al. A specific antidote for dabigatran: functional and structural characterization. Blood 2013; 121 (18) 3554-3562
    CrossrefPubMedGoogle Scholar
  • 75 Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124 (14) 1573-1579
    CrossrefPubMedGoogle Scholar
  • 76 Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012; 108 (02) 217-224
    Article in Thieme ConnectPubMedGoogle Scholar
  • 77 Arellano-Rodrigo E, Lopez-Vilchez I, Galan AM. , et al. Coagulation factor concentrates fail to restore alterations in fibrin formation caused by rivaroxaban or dabigatran in studies with flowing blood from treated healthy volunteers. Transfus Med Rev 2015; 29 (04) 242-249
    CrossrefPubMedGoogle Scholar
  • 78 Schulman S, Ritchie B, Nahirniak S. , et al; Study investigators. Reversal of dabigatran-associated major bleeding with activated prothrombin concentrate: a prospective cohort study. Thromb Res 2017; 152: 44-48
    CrossrefPubMedGoogle Scholar
  • 79 Glund S, Moschetti V, Norris S. , et al. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost 2015; 113 (05) 943-951
    Article in Thieme ConnectPubMedGoogle Scholar
  • 80 Glund S, Stangier J, Schmohl M. , et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet 2015; 386 (9994): 680-690
    CrossrefPubMedGoogle Scholar
  • 81 Pollack Jr CV, Reilly PA, Bernstein R. , et al. Design and rationale for RE-VERSE AD: a phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost 2015; 114 (01) 198-205
    Article in Thieme ConnectPubMedGoogle Scholar
  • 82 Pollack Jr CV, Reilly PA, Eikelboom J. , et al. Idarucizumab for dabigatran reversal. N Engl J Med 2015; 373 (06) 511-520
    CrossrefPubMedGoogle Scholar
  • 83 Pollack Jr CV, Reilly PA, van Ryn J. , et al. Idarucizumab for dabigatran reversal - full cohort analysis. N Engl J Med 2017; 377 (05) 431-441
    CrossrefPubMedGoogle Scholar
  • 84 Brouwers HB, Greenberg SM. Hematoma expansion following acute intracerebral hemorrhage. Cerebrovasc Dis 2013; 35 (03) 195-201
    CrossrefPubMedGoogle Scholar
  • 85 Alhashem HM, Avendano C, Hayes BD, Winters ME. Persistent life-threatening hemorrhage after administration of idarucizumab. Am J Emerg Med 2017; 35 (01) 193.e3-193.e5
    CrossrefPubMedGoogle Scholar
  • 86 Steele AP, Lee JA, Dager WE. Incomplete dabigatran reversal with idarucizumab. Clin Toxicol (Phila) 2017; 1-3
    PubMedGoogle Scholar
  • 87 Simon A, Domanovits H, Ay C, Sengoelge G, Levy JH, Spiel AO. The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran. J Thromb Haemost 2017; 15 (07) 1317-1321
    CrossrefPubMedGoogle Scholar
  • 88 Glund S, Stangier J, van Ryn J. , et al. Effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase Ib study. Clin Pharmacokinet 2017; 56 (01) 41-54
    CrossrefPubMedGoogle Scholar
  • 89 Chai-Adisaksopha C, Hillis C, Lim W, Boonyawat K, Moffat K, Crowther M. Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review. J Thromb Haemost 2015; 13 (10) 1790-1798
    CrossrefPubMedGoogle Scholar
  • 90 Stecher A, Vene N, Mavri A, Mijovski MB, Krevel B, Gradišek P. Late rebound of dabigatran levels after idarucizumab reversal in two patients with severe renal failure. Eur J Anaesthesiol 2017; 34 (06) 400-402
    CrossrefPubMedGoogle Scholar
  • 91 Guyatt GH, Oxman AD, Vist GE. , et al; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336 (7650): 924-926
    CrossrefPubMedGoogle Scholar
  • 92 Xarelto (R) [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2017
    PubMed
  • 93 Eliquis (R) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2016
    PubMed
  • 94 Savaysa (R) [package insert]. Parsippany, NJ: Daiichi Sankyo, Inc.; 2016
    PubMed
  • 95 Bevyxxa (R) [package insert]. South San Francisco, CA: Portola Pharmaceuticals, Inc; 2017
    PubMed
  • 96 Robertson L, Kesteven P, McCaslin JE. Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism. Cochrane Database Syst Rev 2015; (12) CD010957
    PubMedGoogle Scholar
  • 97 Held C, Hylek EM, Alexander JH. , et al. Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. Eur Heart J 2015; 36 (20) 1264-1272
    CrossrefPubMedGoogle Scholar
  • 98 Bruins Slot KM, Berge E. Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation. Cochrane Database Syst Rev 2013; (08) CD008980
    PubMedGoogle Scholar
  • 99 Cheung YW, Barco S, Hutten BA, Meijers JC, Middeldorp S, Coppens M. In vivo increase in thrombin generation by four-factor prothrombin complex concentrate in apixaban-treated healthy volunteers. J Thromb Haemost 2015; 13 (10) 1799-1805
    CrossrefPubMedGoogle Scholar
  • 100 Martin A-C, Gouin-Thibault I, Siguret V. , et al. Multimodal assessment of non-specific hemostatic agents for apixaban reversal. J Thromb Haemost 2015; 13 (03) 426-436
    CrossrefPubMedGoogle Scholar
  • 101 Halim A-B, Samama MM, Mendell J. Ex vivo reversal of the anticoagulant effects of edoxaban. Thromb Res 2014; 134 (04) 909-913
    CrossrefPubMedGoogle Scholar
  • 102 Lu G, DeGuzman FR, Hollenbach SJ. , et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013; 19 (04) 446-451
    CrossrefPubMedGoogle Scholar
  • 103 Crowther M, Levy GG, Lu G. , et al. A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of edoxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), a universal antidote for factor Xa (fXa) inhibitors. Blood 2013; 124: 4269
    PubMedGoogle Scholar
  • 104 Crowther M, Vandana M, Michael K. , et al. A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for FXa inhibitors. Blood 2013; 122: 3636
    PubMedGoogle Scholar
  • 105 Crowther M, Lu G, Conley P. , et al. Sustained reversal of apixaban anticoagulation with andexanet alfa using a bolus plus infusion regimen in a phase 2 placebo controlled trial. Eur Heart J 2014; 35 (Suppl. 01) 137
    CrossrefPubMedGoogle Scholar
  • 106 Siegal DM, Curnutte JT, Connolly SJ. , et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 2015; 373 (25) 2413-2424
    CrossrefPubMedGoogle Scholar
  • 107 Connolly SJ, Milling Jr TJ, Eikelboom JW. , et al; ANNEXA-4 Investigators. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 2016; 375 (12) 1131-1141
    CrossrefPubMedGoogle Scholar
  • 108 News Release: Portola Pharmaceutical Receives Complete Response Letter from FDA for Biologics License Application for AndexXa™ (andexanet alfa). Portola Pharmaceuticals, Inc. Available at: http://investors.portola.com/phoenix.zhtml?c=198136&p=irol-newsroomArticle&ID=2196085 . Updated August 18, 2016. Accessed July 5, 2017
    PubMed
  • 109 Lu G, Pine P, DeGuzman F. , et al. Reversal of anticoagulation effects of rivaroxaban and associated bleeding in a rabbit acute hemorrhage model by andexanet alfa vs. coagulation replacement factors. Neurology 2017; 88 (16 Supplement P5.054): 1526-1632
    PubMedGoogle Scholar
  • 110 Lu G, Kotha J, Cardenas JM. , et al. In vitro characterization of andexanet alfa (PRT064445), a specific fXa inhibitor antidote versus aripazine (PER977), a non-specific reversal agent. Circulation 2014; 130: A18218
    PubMedGoogle Scholar
  • 111 Ansell JE, Bakhru SH, Laulicht BE. , et al. Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban. Thromb Haemost 2017; 117 (02) 238-245
    Article in Thieme ConnectPubMedGoogle Scholar
  • 112 Study of Ciraparantag Administered to Volunteers Anticoagulated With Rivaroxaban. Measure Clotting Times Using WBCT. ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT03172910 . Updated May 30, 2017. Accessed July 6, 2017
    PubMedGoogle Scholar